Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained widespread use in the treatment of individuals with type 2 diabetes because of their potent weight loss promoting effect, ability to augment β-cell function, and cardiovascular protective effects. However, despite causing impressive weight loss, GLP-1 receptor agonists do not normalise insulin sensitivity in people with type 2 diabetes and obesity, and the long-term effects of this class of antidiabetic medication on muscle mass, frailty, and bone density have been poorly studied. Although GLP-1 receptor agonists improve insulin sensitivity secondary to weight loss, the only true direct insulin-sensitising drugs are thiazolidinediones. Because of side-effects associated with type 2 diabetes therapy, these drugs have not gained widespread use. In lieu of the important role of insulin resistance in the cause of type 2 diabetes and in the pathogenesis of atherosclerotic cardiovascular disease in type 2 diabetes, development of potent insulin-sensitising drugs that can be used in combination with GLP-1 receptor agonists remains a large unmet need in the management of individuals with type 2 diabetes.

• Publication year

  2024

• Venue

  The Lancet Diabetes and Endocrinology

• Publication date

  2024-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/s2213-8587(24)00127-xPMID 39098317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin sensitizers in 2023: lessons learned and new avenues for investigation

  2023cited by this paper
• Trends in the Prevalence of Lean Diabetes Among U.S. Adults, 2015-2020.

  2023cited by this paper
• Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

  2023cited by this paper
• Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

  2023cited by this paper
• Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes

  2022cited by this paper
• Why does obesity cause diabetes?

  2022cited by this paper
• Association Between Visceral Adiposity Index and Insulin Resistance: A Cross-Sectional Study Based on US Adults

  2022cited by this paper
• The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study

  2022cited by this paper
• Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.

  2022cited by this paper
• Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice

  2022cited by this paper
• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

  2022cited by this paper
• New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications

  2021cited by this paper
• GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.

  2021cited by this paper
• Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.

  2021cited by this paper
• The aetiology and molecular landscape of insulin resistance

  2021cited by this paper
• Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT

  2020cited by this paper
• Causes, consequences, and treatment of metabolically unhealthy fat distribution.

  2020cited by this paper
• Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

  2020cited by this paper
• Trends in the prevalence of overweight, obesity, and abdominal obesity among Chinese adults between 1993 and 2015

  2020cited by this paper
• Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology

  2020cited by this paper
• Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

  2020cited by this paper
• Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

  2019cited by this paper
• Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide.

  2019cited by this paper
• Pioglitazone Improved Insulin Sensitivity and First Phase Insulin Secretion Among Obese and Lean People with Diabetes: A Multicenter Clamp Study

  2018cited by this paper
• Paradigm Change to Future Health Enhancement through Comprehending the Concept of Obesity Disease in Japan

  2018cited by this paper
• Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes

  2018cited by this paper
• Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study

  2018cited by this paper
• Muscle and Bone Mass Loss in the Elderly Population: Advances in diagnosis and treatment.

  2018cited by this paper
• Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes

  2017cited by this paper
• Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor

  2017cited by this paper
• The Multifaceted Roles of Adipose Tissue—Therapeutic Targets for Diabetes and Beyond: The 2015 Banting Lecture

  2016cited by this paper
• Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

  2016cited by this paper
• The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.

  2016cited by this paper
• Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial

  2015cited by this paper
• Type 2 diabetes mellitus

  2015cited by this paper
• Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

  2014cited by this paper
• Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

  2013cited by this paper
• Frailty in elderly people.

  2013cited by this paper
• Pharmacology, physiology, and mechanisms of incretin hormone action.

  2013cited by this paper
• Insulin Resistance and Risk of Incident Cardiovascular Events in Adults without Diabetes: Meta-Analysis

  2012cited by this paper
• Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

  2012cited by this paper
• A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance

  2012cited by this paper
• Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.

  2012cited by this paper
• Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes

  2011cited by this paper
• Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

  2011cited by this paper
• Biology of human sodium glucose transporters.

  2011cited by this paper
• Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.

  2011cited by this paper
• Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

  2010cited by this paper
• Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

  2010cited by this paper
• Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.

  2010cited by this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management.

  2009cited by this paper
• Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis.

  2009cited by this paper
• Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

  2007cited by this paper
• Increasing trends in incidence of overweight and obesity over 5 decades.

  2007cited by this paper
• Thiazolidinediones improve -cell function in type 2 diabetic patients

  2007cited by this paper
• beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.

  2004cited by this paper
• Medical consequences of obesity.

  2004cited by this paper
• Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S.

  2004cited by this paper
• Muscle tissue changes with aging

  2004cited by this paper
• Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance

  2004cited by this paper
• Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.

  2004cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

  2003cited by this paper
• Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

  2003cited by this paper
• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  2002cited by this paper
• Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation.

  2001cited by this paper
• Body-Mass Index and Mortality in a Prospective Cohort of US Adults

  2000cited by this paper
• Body-mass index and mortality in a prospective cohort of U.S. adults.

  1999cited by this paper
• Metformin: A review of its metabolic effects

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Genotype-stratified treatment for monogenic insulin resistance: a systematic review

  1997cited by this paper
• Clinical profile of lean NIDDM in South India.

  1997cited by this paper
• Weight change and diabetes incidence: findings from a national cohort of US adults.

  1997cited by this paper
• Immunoassay of endogenous plasma insulin in man.

  1996cited by this paper
• Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

  1996cited by this paper
• Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus.

  1995cited by this paper
• Reciprocal Variations in Insulin-Stimulated Glucose Uptake and Pancreatic Insulin Secretion in Women With Normal Glucose Tolerance

  1995cited by this paper
• Quantification of the Relationship Between Insulin Sensitivity and β-Cell Function in Human Subjects: Evidence for a Hyperbolic Function

  1993cited by this paper
• Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

  1992cited by this paper
• The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents.

  1992cited by this paper
• The Metabolic Profile of NIDDM Is Fully Established in Glucose-Tolerant Offspring of Two Mexican-American NIDDM Parents

  1992cited by this paper
• The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus.

  1991cited by this paper
• Obesity and insulin resistance in humans: a dose-response study.

  1990cited by this paper
• Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.

  1989cited by this paper
• Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

  1989cited by this paper
• Role of Insulin Resistance in Human Disease

  1988cited by this paper
• Banting lecture 1988. Role of insulin resistance in human disease.

  1988cited by this paper
• The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM

  1988cited by this paper
• Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.

  1985cited by this paper
• A Comparison of the Relative Effects of Obesity and Non-insulin-dependent Diabetes Mellitus on In Vivo Insulin-stimulated Glucose Utilization

  1984cited by this paper
• Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes.

  1979cited by this paper
• Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding.

  1978cited by this paper
• Diabetes Mellitus: Incidence, Prevalence, Survivorship, and Causes of Death in Rochester, Minnesota, 1945–1970

  1976cited by this paper
• Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia.

  1975cited by this paper
• Further Evidence that Insulin Resistance Exists in Patients with Chemical Diabetes

  1974cited by this paper
• PERIPHERAL METABOLISM OF GLUCOSE AND FREE FATTY ACIDS DURING ORAL GLUCOSE TOLERANCE TESTS.

  1965cited by this paper

• Effects of aerobic exercise on integrated cardiovascular health and energy metabolism in patients with type 2 diabetes mellitus: study protocol for a randomized controlled trial

  2026cites this paper
• Associations of triglyceride-glucose index and hs-CRP with incident aortic valve calcification and mortality in Kailuan study population: a nationwide prospective cohort study

  2026cites this paper
• Exercise Suppresses Insulin Resistance: A Potential Mechanism for Improving the Interaction Between Type 2 Diabetes and Alzheimer's Disease.

  2026cites this paper
• The synergistic effect of the triglyceride-glucose index and a body shape index on cardiovascular mortality: the construction of a novel cardiovascular risk marker

  2025cites this paper
• Prediabetes remission to reduce the global burden of type 2 diabetes.

  2025cites this paper
• Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study

  2025cites this paper
• Branched-chain amino acids in obesity and diabetes: Implications and insights

  2025cites this paper
• Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?

  2025cites this paper
• SGLT-2i—A Useful Tool for Real-Life Metabolic and Body Weight Control in Type 2 Diabetes Mellitus Patients

  2025cites this paper
• Metabolomic network reveals novel biomarkers for type 2 diabetes mellitus in the UK Biobank study

  2025cites this paper
• Insulin resistance quantified by estimated glucose disposal rate predicts cardiovascular disease incidence: a nationwide prospective cohort study

  2025cites this paper
• Strawberries improve insulin resistance and related cardiometabolic markers in adults with prediabetes: a randomized controlled crossover trial.

  2025cites this paper
• Metabolic and Vascular Insulin Resistance: Partners in the Pathogenesis of Cardiovascular Disease in Diabetes.

  2025cites this paper
• Association of triglyceride-glucose-related indices with adverse clinical outcomes in individuals with normal body mass index

  2025cites this paper
• A novel fullerene-lysine derivative with noticeable ROS scavenging capabilities for improving type 2 diabetes mellitus

  2025cites this paper
• Development and validation of a novel glucolipid metabolism-related nomogram to enhance the predictive performance for osteoporosis complications in prediabetic and diabetic patients

  2025cites this paper
• Associations of Estimated Glucose Disposal Rate With Stroke Risk and Poststroke Adverse Outcomes: A Prospective Cohort Study

  2025cites this paper
• Fungal Xylomannan as a Dietary Supplement: Activates Hepatic AMPK/HIF-1α Signaling to Attenuate Insulin Resistance

  2025cites this paper
• Design and evaluation of novel thiazolidinedione-oxadiazole derivatives as potent α-amylase inhibitors for antidiabetic therapy

  2025cites this paper
• Associations of metabolic obesity phenotypes with cognitive aging in middle-aged and elderly Chinese adults.

  2025cites this paper
• First metatarsophalangeal joint synovial hypertrophy associated with vitamin D status in type 2 diabetes mellitus: An ultrasound-graded study

  2025cites this paper
• Influence of Hydrophobic Ion Pairing on Formulation Performance of Liraglutide in PLGA Microspheres

  2025cites this paper
• Circulating BCKAs are closely associated with adipose tissue insulin resistance in type 2 diabetes

  2025cites this paper
• Ethnic diversity in precision medicine: a reality or an aspiration?

  2025cites this paper
• Partially Hydrolyzed Guar Gum Combined with a Low-Fat Diet Ameliorates Type 2 Diabetes Mellitus via Modulating Gut Microbiota and Fecal Metabolites

  2025cites this paper
• Unlocking the Link Between Gut Microbiota and Psychopathological Insights in Anorexia Nervosa: A Systematic Review.

  2025cites this paper
• Metabolic dysfunction and insulin sensitizers in acute and chronic disease

  2025cites this paper
• Aetiological clustering of newly diagnosed type 2 diabetes using machine learning: a retrospective cross-sectional study in Dubai, UAE

  2025cites this paper
• The Double-Edged Sword of Gestational Insulin Resistance: Navigating Maternal Adaptation and Its Risks for Pregnancy and Offspring Health.

  2025cites this paper
• Metabolic crossroads in insulin resistance: exploring lipid dysregulation and inflammation

  2025cites this paper
• Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease

  2025cites this paper
• The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance

  2025cites this paper
• Pharmacologic Therapies for Type 2 Diabetes

  2025cites this paper
• Glia maturation factor-β deficiency improves insulin resistance by promoting CARM1-mediated lipid turnover.

  2025cites this paper
• Organs-on-a-Chip Recapitulating the Gut–Islets Axis for Endocrine Hormone Secretion Regulator Evaluation

  2025cites this paper
• Therapeutic potential of traditional Chinese medicine and mechanisms for the treatment of type 2 diabetes mellitus

  2025cites this paper
• Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study

  2025cites this paper
• High predicted cardiac event risk in youth with obesity and type 2 diabetes: a pooled cohort analysis

  2025cites this paper
• The association between triglyceride glucose–body mass index and all–cause mortality in critically ill patients undergoing cardiac surgery: a retrospective analysis from the MIMIC–IV database

  2025cites this paper
• Tracing the Path from Obesity to Diabetes: How S-Allyl Cysteine Shapes Metabolic Health

  2025cites this paper
• Insulin Resistance Indices Predict Mortality in Cardiovascular Disease: A Large‐Scale NHANES Study With Machine Learning Validation

  2025cites this paper
• Risk of Nephrolithiasis Associated With SGLT2 Inhibitors Versus DPP4 Inhibitors Among Patients With Type 2 Diabetes: A Target Trial Emulation Study.

  2024cites this paper
• Insulin Resistance–Nutritional Index: A Simple Index and Potential Predictor of Mortality Risk in Patients with Chronic Heart Failure and Type 2 Diabetes

  2024cites this paper
• The Etiology of Reduced Muscle Mass with Surgical and Pharmacological Weight Loss and the Identification of Potential Countermeasures

  2024cites this paper
• World Journal of Diabetes

  year unknowncites this paper
• World Journal of Diabetes

  year unknowncites this paper